Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

CLI opened at GBX 64.91 ($0.84) on Tuesday. The firm’s 50 day moving average is GBX 71.54 and its 200-day moving average is GBX 81.52. CLS has a 52-week low of GBX 62.50 ($0.81) and a 52-week ...

Silexion Therapeutics Corp. has announced an expanded development plan for its next-generation siRNA candidate SIL-204. The new dual-route strategy will integrate intratumoral and systemic ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a micro-cap biotechnology firm with a market capitalization of $9.93 million focused on RNA interference (RNAi) therapies, has announced an ...

Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and ...